brolucizumab
Selected indexed studies
- Brolucizumab. (, 2006) [PMID:32105421]
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (Ophthalmology, 2020) [PMID:30986442]
- Brolucizumab: First Approval. (Drugs, 2019) [PMID:31768932]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brolucizumab. (2006) pubmed
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (2020) pubmed
- Brolucizumab: First Approval. (2019) pubmed
- Brolucizumab for the treatment of diabetic macular edema. (2022) pubmed
- KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. (2022) pubmed
- PMID:40737461 (2021) pubmed
- Side Effects of Brolucizumab. (2021) pubmed
- PMID:37883618 (2023) pubmed
- Brolucizumab in polypoidal choroidal vasculopathy. (2022) pubmed
- Brolucizumab for macular degeneration. (2020) pubmed